SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas Life Sciences Group is currently the top trending ticker as investors debate the impact of trial protocol modifications on its REGAL Phase 3 study and upcoming AACR presentation. While some community members highlight potential long-term clinical efficacy and a possible buyout, others express strong skepticism regarding the trial's design and management's transparency.

Daddy Darth Sidious

Investors are fueling speculation around SIDIOUS and DARTH, with the community actively debating whether a sector-wide rotation away from rival tokens is underway. Discussions are centered on potential momentum plays as participants urge others to buy the dip while navigating concerns over market volatility and project sustainability.

The Last Play is Crypto’s 401k.  RETIRE is more than a coin; it’s The Last Play. We are a community dedicated to breaking free from the grind and building true generational wealth. With RETIRE, our mission is simple yet profound: to provide a pathway to retire yourself and secure financial freedom for your bloodline. While others chase hype and trends, we’re focused on creating a legacy that lasts beyond the typical cycle. RETIRE is about making the one move that matters, with a vision for long-term value, freedom, and impact. This isn’t just a meme —it’s a purpose-driven commitment to building a legacy.

The Last Play

Investors are rallying behind $RETIRE as a tokenized alternative to traditional retirement plans, positioning it as a movement against the established financial system. The community is actively building momentum through weekly dollar-cost averaging and frequent social media campaigns, driven by hopes for significant long-term growth and financial independence.

The 401jK (just kidding) meme is a satirical punch in the gut in the face of the concept of retirement and the popular US based 401(k) retirement plan and other pension plans around the world  Through the meme fueled humor, irony, satire &amp; inspiration from cypherpunk ideology, real life data, and current events... the 401jK community aims to comment on the fact that global markets are heavily manipulated for selfish purposes by the same people who control these pension funds... while also aiming to twist the heads of the 401k and global pension systems.  It is a retirement plan that seeks to make social, political, economic commentary fueled by the memes and dreams of the hive mind of the community that makes up 401jK  The rules have changed, and the game was always rigged.  It's time to wake up, adapt, rebel, and heal.  Welcome to 401jK

401jK

The 401jK community is actively promoting its meme-centric narrative as a defiant alternative to traditional, broken retirement systems. Investors are debating the project's long-term utility versus its high volatility, while the community continues to focus on grassroots educational initiatives and widespread IRL marketing.

Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.

Bicycle Therapeutics Plc - ADR

Bicycle Therapeutics is trending as investors focus on upcoming clinical data from the AACR conference, particularly concerning its lead asset BT5528 in combination studies. While community sentiment is divided between optimism regarding its strong cash runway and the potential of its radiopharma pivot versus concerns over past regulatory hurdles and pipeline restructuring, the stock remains a high-interest subject for those weighing binary biotech risk against a solid balance sheet.

Daddy Darth Vader

DARTH is currently driving intense community speculation amid a "daddy war" rivalry with $MAULCOIN, with participants actively debating the token's long-term viability versus its nature as a high-risk trading opportunity. While some investors focus on liquidity building and potential parabolic gains, others express strong skepticism, labeling the project a potential scam or pump-and-dump scheme.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending as investors monitor the anticipation of the April 30, 2026, PDUFA date for AXS-05, a pivotal regulatory catalyst for Alzheimer's disease-associated agitation. The community is actively discussing the company's aggressive expansion of its sales force and strong prescription growth for Auvelity, while analysts continue to adjust price targets upward in response to high conviction in the drug's approval prospects.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion is gaining significant market attention as investors highlight its strategic partnerships with NVIDIA and its development of quantum sensing technology for defense and space applications. The community is actively discussing the stock's potential for a valuation re-rating, often comparing its current market cap to other quantum sector peers while noting its recent inclusion in high-profile quantum AI initiatives.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

Compound is currently a major focus for traders due to its limited circulating supply and anticipation surrounding upcoming protocol updates and governance catalysts. Community sentiment is deeply polarized, with some investors betting on a long-term turnaround fueled by potential institutional adoption, while others are actively warning about prolonged price stagnation and competition from rival DeFi protocols.

Fermi, Inc. engages in the development of energy infrastructure. It intends to develop an energy and data center development campus to support the needs of to-be-built AI infrastructure. The company was founded by Rick Perry, Toby Neugebauer and Griffin Perry on January 10, 2025 and is headquartered in Amrillo, TX.

Fermi Inc

Fermi LLC

Investors are actively debating the future of Fermi LLC following the sudden departure of CEO Toby Neugebauer and ongoing concerns over the lack of a secured anchor tenant for their data center project. While some community members view the leadership change as a bullish catalyst for operational reform, others remain skeptical, citing continued regulatory uncertainty and speculative stock volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$IFRX interesting link from Staidson BDB-001 (IFRX-1) - did not know that they started a phase I/II study 3 weeks ago in HS
A Multicenter, Randomized, Double-blind, Placebo Parallel-controlled, Phase I/II Study to Explore Safety and Efficacy of BDB-001 Injection in Subjects With Moderate to Severe Hidradenitis Suppurativa
https://drugsheet.com/?time=Past+Month&amp;phase=2&amp;intervention=BDB-001

John K.

CIELO1

Paul Stevenson

aecids

paradigman

Ivan

Drugsheet

StockTwits For Android 

InflaRx N.V.

 interesting link from Staidson BDB-001 (IFRX-1) - did not know that they started a phase I/II study 3 weeks ago in HS
A Multicenter, Randomized, Double-blind, Placebo Parallel-controlled, Phase I/II Study to Explore Safety and Efficacy of BDB-001 Injection in Subjects With Moderate to Severe Hidradenitis Suppurativa


@lichily Yes, here are the official links:
 
https://clinicaltrials.gov/ct2/show/NCT05093855?term=bdb-001&amp;draw=2&amp;rank=4
 
https://clinicaltrials.gov/ct2/show/NCT05103423?term=bdb-001&amp;draw=2&amp;rank=6
 
I suspect it has something to do with Lina Ma&#39;s resignation:
 
https://www.sec.gov/Archives/edgar/data/1708688/000114036121031347/brhc10028984_6k.htm
 
Remember: InflaRx has all global rights outside China to any and all discoveries derived from the development of BDB-001 in China.

Kevin

Primary Outcome Measures : Changes in INAPP (Inflammatory Nodules, Abscesses, Pyorrhea, Pain VAS) score relative to baseline [ Time Frame: Week 8 ] INAPP Score=(Inflammatory Nodule Count) + (Abscess Count*2) + (Pyorrhea *2)+（Pain VAS).The higher the score the more severe is the disease/worse is the outcome.

Clinicaltrials

Efficacy and Safety Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS) - Full Text View - ClinicalTrials.gov

Primary Outcome Measures : Number of participants with treatment-related adverse events as assessed by CTCAE v5.0. [ Time Frame: Week 8 ] Safety and tolerability of BDB-001 injection after multiple administration in the treatment of HS patients. Number of Participants developing anti-BDB-001 antibodies.

Safety and Efficacy Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS) - Full Text View - ClinicalTrials.gov

SECURITIES AND EXCHANGE COMMISSION REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2021 Commission File Number: 001-38283 (Translation of registrant's name into English) (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

StockTwits for iOS


 
I suspect it has something to do with Lina Ma's resignation:
 



 
Remember: InflaRx has all global rights outside China to any and all discoveries derived from the development of BDB-001 in China.

SPDR S&P Biotech ETF

@Lexy911  excellent - thank you! BTW do you remember if there are any potential royalties for InflaRx on BDB-001 sales in China?

  excellent - thank you! BTW do you remember if there are any potential royalties for InflaRx on BDB-001 sales in China?

@lichily BDB shall be granted appropriate usage rights under InflaRx Intellectual Property to the extent necessary for development, manufacture and Commercialization of BDB-1 and BDB-2 solely inside the BDB Territory and pay in return royalties to INFLARX as set forth in this Agreement.

Please also read paragraph 7.8.

https://www.sec.gov/Archives/edgar/data/1708688/000095010317010902/dp82624_ex1003.htm

Jana Klar

INFLARX - BDB contract - confidential information page 1 of 33 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. [*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMMITTED MATERIAL HAS BEEN FILED SEPERATELY WITH THE COMMISSION.

 BDB shall be granted appropriate usage rights under InflaRx Intellectual Property to the extent necessary for development, manufacture and Commercialization of BDB-1 and BDB-2 solely inside the BDB Territory and pay in return royalties to INFLARX as set forth in this Agreement.

Please also read paragraph 7.8.



@Lexy911 that&#39;s fantastic - thanks for the details!

 that's fantastic - thanks for the details!